Article Text

PDF
OC-066 Economic and quality-of-life burden of moderate-to-severe irritable bowel syndrome with constipation (ibs-c) in the uk: the ibis-c study
  1. Y Yiannakou1,
  2. M Eugenicos2,
  3. DS Sanders3,
  4. A Emmanuel4,
  5. P Whorwell5,
  6. F Butt6,
  7. S Bridger7,
  8. N Arebi8,
  9. A Millar9,
  10. V Kaushik10,
  11. M Rance11,
  12. J Mackinnon12,
  13. J Bertsch12,
  14. J Fortea11,
  15. J Tack13
  1. 1University Hospital of North Durham, Durham
  2. 2Western General Hospital, Edinburgh
  3. 3Royal Hallamshire Hospital, Sheffield
  4. 4University College Hospital, London
  5. 5Wythenshawe Hospital, Manchester
  6. 6South Tyneside NHS Trust, South Shields
  7. 7Dorset County Hospital, Dorchester
  8. 8St Mark’s Hospital, Harrow
  9. 9North Middlesex University Hospital, London
  10. 10Royal Blackburn Hospital, Blackburn, UK
  11. 13University Hospital Gasthuisberg, Leuven, Belgium
  12. 11Almirall SA
  13. 12TFS Develop S. L, Barcelona, Spain

Abstract

Introduction This is the first study to assess the burden of IBS-C in 6 European countries (France, Germany, Italy, Spain, Sweden, UK). Here we present the results for the UK.

Method Observational, retrospective-prospective (6 months each) study in patients (pts) diagnosed with IBS-C in the last five years (Rome-III criteria) and moderate-to-severe symptoms at baseline: IBS-Symptom Severity Score (IBS-SSS) ≥175. Health resource utilisation was retrospectively and prospectively assessed. Symptom evolution was assessed in the prospective period, and quality-of-life (QoL) was assessed at baseline with EuroQoL-5D (EQ-5D) and IBS-QoL. Work productivity was prospectively assessed using the Work Productivity and Activity Impairment (WPAI): IBS-C questionnaire.

Results 104 pts were included (79% severe, mean age [± SD] 45.5 ± 14.6 yrs, 93% female). At baseline, symptom severity (IBS-SSS; severe >300) was 373.1 ± 82.5; presenteeism (WPAI:IBS-C; mean ± SD): 47.9% ± 28.7%; absenteeism: 8.4% ± 24.2%; work productivity loss: 51.5% ± 27.2%; daily activity impairment: 56.8% ± 29.6%. Mean IBS-QoL was 57.2 ± 24.2, (scale: 0–100 [best-to-worst]) and mean EQ-5D was 54.0 ± 23.3 (scale: 0–100 [worst-to-best]. 87.5% and 64.4% of pts reported moderate-to-severe problems in pain/discomfort, anxiety/depression respectively. Most prevalent symptoms were abdominal pain (92%) and bloating (91%). 70% pts consulted a GP, and 100% a gastroenterologist; mean: 6.2 and 2.7 visits, respectively. 24% pts required emergency department visits or hospitalisation (mean stay [95% CI]: 12 [2.5–21.1] days). 52% had a diagnostic test (mean [95% CI]: 3.6 [2.9–4.4]). 90% pts took prescription drugs for IBS-C. Mean (95% CI) annual direct cost for the NHS: £ 1753 (1251–2308); the mean pt cost: £ 315 (184–482). 51% of pts took sick leave (mean: 5.2 times; mean duration: 26 days) and 82% had productivity losses (mean: 162 h). Mean indirect costs were £ 3407 (2078–4977). Total costs amounted to £ 5443 (3970–7252)/year.

Conclusion Moderate-to-severe IBS-C has a major impact on patient QoL, productivity, and healthcare resource utilisation.

Disclosure of interest Y. Yiannakou Conflict with: Grants: Shire; Medtronic. Speaker fees: Almirall; Shire; Sucampo, M. Eugenicos Conflict with: Consultant/Advisory Board Member: Almirall; Astellas; Dr Falk Pharma; NAPP; and Shire, D. Sanders Consultant for: Almirall, A. Emmanuel Conflict with: Advisory Board and Educational Talk honoraria: Almirall., P. Whorwell Conflict with: Consultant/research grant support: Almirall; Chr. Hansen; Danone Research; Ironwood; Salix; Shire; Sucampo, F. Butt: None Declared, S. Bridger: None Declared, N. Arebi: None Declared, A. Millar Conflict with: The hospital received payment from Almirall for the conduct of the study, V. Kaushik Conflict with: Advisory Board and Educational Talk honoraria: Almirall. Meeting support: Cooks; Tillotts; AbbVie., M. Rance Employee of: Almirall, J. Mackinnon Employee of: TFS Develop S. L., contracted by Almirall S. A to conduct the study, J. Bertsch Employee of: TFS Develop S. L, contracted by Almirall S. A. to conduct the study, J. Fortea Employee of: Almirall, J. Tack Conflict with: Grants/research support: Abbott; Novartis; Shire. Honoraria/consultancy fees: Almirall; AstraZeneca; Danone; GI Dyamics; GlaxoSmithKline; Ironwood; Janssen; Menarini; Novartis; Rhythm; Shire; Takeda; Theravance; Tsumura; Will Pharma; Zeria. Speaker fees: Abbott; Almirall; AstraZeneca; Janssen; Menarini; Novartis; Shire; Takeda; Zeria.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.